Skip to content

Tango Therapeutics TNGX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN
Gilead Sciences logo
Gilead SciencesGILD
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
CG Oncology logo
CG OncologyCGON
Lantheus Holdings logo
Lantheus HoldingsLNTH

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's deferred tax assets and other non-current assets?
Tango Therapeutics (TNGX) reported deferred tax assets and other non-current assets of $293K in Q1 2026.
How has Tango Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
Tango Therapeutics's deferred tax assets and other non-current assets increased by 29200.0% year-over-year, from $1K to $293K.
What is the long-term trend for Tango Therapeutics's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Tango Therapeutics's deferred tax assets and other non-current assets has grown at a 51.5% compound annual growth rate (CAGR), from $38K to $303K.